Abstract
Dantrolene, an FDA approved drug to treat malignant hyperthermia and muscle spasm, has been demonstrated to inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mediated toxicity of host cells. Ryanodine receptor overactivation and associated disruption of intracellular Ca2+ homeostasis play important roles in SARS-CoV-2 infection and replication of host cells. Dantrolene, as an inhibitor of RyRs, is expected to ameliorate these detrimental effects of SARS-CoV-2 in host cells. Additionally, dantrolene has also been shown to inhibit multiple cell or organ damage induced by hypoxia/ischemia, mitochondria damage, oxidative stresses, inflammation, impairment of autophagy and apoptosis, etc., which are often the causes of severity and mortality of COVID-19 patients. We have repurposed that dantrolene has a high potential at treating COVID-19 patients and reducing its morbidity and mortality.
【초록키워드】 SARS-CoV-2, Apoptosis, Inflammation, Mitochondria, coronavirus, Mortality, hypoxia, SARS-COV-2 infection, severity, Toxicity, severe acute respiratory syndrome Coronavirus, FDA, autophagy, Replication, morbidity and mortality, receptor, respiratory, inhibitor, homeostasis, COVID-19 patients, Ischemia, host cells, Dantrolene, muscle spasm, malignant hyperthermia, acute respiratory syndrome, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, causes, treat, organ damage, impairment, hyperthermia, Cell, oxidative stresses, Ryanodine, shown, inhibit, approved, reducing, demonstrated, cause, expected, detrimental effect, intracellular Ca2+, treating COVID-19 patient, 【제목키워드】 COVID-19 patient, treat, intracellular calcium,